Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388633 · ClinicalTrials.gov registry record
Acute Microvascular Changes With LDL Apheresis
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 8
- Enrollment target
NCT02388633 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants.
The verdict
NCT02388633 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Severe hypercholesterolemia produced by conditions such as heterozygous familial hypercholesterolemia is associated with multiple complications including premature atherosclerotic disease. There is evidence that microvascular perfusion, particularly flow reserve, in critical organs is limited due to abnormalities in plasma viscosity, abnormal RBC deformability, and an imbalance between vasodilators and vasoconstrictors. There is little is currently known about acute changes in microvascular blood flow and microvascular rheology that occur in response to plasmapharesis which is used in some patients to lower critically elevated cholesterol levels. Our research group has pioneered CEU methods for assessing myocardial and skeletal muscle perfusion, and has previously demonstrated in pre-clinical models that acute hyperlipidemia produces a reduction in microvascular RBC transit rate. In this study, the investigators will assess acute changes in microvascular perfusion in patients undergoing clinically-indicated plasmapharesis.
Interventions
- PROCEDURE Plasmapharesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-03-01 |
| Est. Completion | 2018-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02388633
The ClinicalTrials.gov registry entry for NCT02388633 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasmapharesis is the first listed.
NCT02388633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02388633 about?
NCT02388633 is a clinical study titled "Acute Microvascular Changes With LDL Apheresis". Severe hypercholesterolemia produced by conditions such as heterozygous familial hypercholesterolemia is associated with multiple complications including premature atherosclerotic disease. There is evidence that microvascular perfusion, particularly flow reserve, in critical organs is limited due to...
What is the current status of trial NCT02388633?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2015-03-01. Estimated completion is 2018-07-01.
What interventions are being tested in trial NCT02388633?
The interventions under investigation include: Plasmapharesis (PROCEDURE).
Who is sponsoring clinical trial NCT02388633?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.